09926.HK
Akeso, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 83.50
−1.82%Oct 27, 2026, 08:12 UTC
Hong Kong-listed shares showed mixed moves, including Xiaomi Corp. falling 4.6% and China Construction Bank, CK Infrastructure and H&H International Holdings reaching record highs.
Source:Oct 27, 2026, 04:12 UTC
Hong Kong-listed shares showed varied moves at midday, including Xiaomi Corp. down 4.2%, Lenovo Group Ltd. up 5.8%, and Duality Biotherapeutics, Inc. down 29.4%.
Source:Oct 26, 2026, 04:22 UTC
Alphamab Oncology announced clinical study results: as of June 20, the China Phase I/II JSKN033-102 study had enrolled 64 patients with cervical cancer whose disease had failed standard treatment, who received JSKN033 monotherapy; the results were presented as a rapid oral presentation at the 2026 ESMO Congress.
Source:Oct 26, 2026, 04:12 UTC
Hong Kong-listed shares showed mixed moves at the half-day close, with Meituan up 3.1% and China Life Insurance up 6.1%, while Zijin Mining fell 5.8%.
Source:Oct 22, 2026, 04:12 UTC
Hong Kong stocks fell at midday, with the Hang Seng Index down 679 points (2.9%) to 22,971, the Hang Seng Tech Index down 185 points (4.6%) to 3,809, and the Hang Seng China Enterprises Index down 248 points (3.1%) to 7,695.
Oct 15, 2026, 08:12 UTC
Among other active Hong Kong-listed shares, Lenovo Group Ltd. fell 14.5% to HK$25.98, Hua Hong Semiconductor fell 7.8% to HK$76.55, Weichai Power fell 6.9% to HK$24.62, China Molybdenum fell 6.8% to HK$14.19, China Hongqiao fell 6.7% to HK$19.51, Aluminum Corporation of China fell 6.3% to HK$7.18, Akeso, Inc. fell 4.7% to HK$90.45, Baidu, Inc. fell 4.5% to HK$78.35, SMIC fell 4.0% to HK$52.15, CATL fell 3.9% to HK$448.60, XPENG INC. fell 3.7% to HK$37.20, Agricultural Bank of China rose 3.5% to HK$6.80, a record high, Orient Overseas fell 3.2% to HK$162.80, Kuaishou fell 3.2% to HK$28.58, and Horizon Robotics fell 3.0% to HK$3.83.
Source:Oct 14, 2026, 10:25 UTC
Southbound Stock Connect flows recorded net inflows of HK$1.19 billion to Alibaba, HK$772 million to Akeso, Inc. and HK$278 million to Meituan, and net outflows of HK$785 million from SMIC, HK$493 million from Yangtze Optical Fibre and Cable and HK$487 million from Xiaomi.
Source:Oct 14, 2026, 09:58 UTC
Southbound funds recorded net sales of HK$135 million in Hong Kong stocks, with net purchases of Alibaba, Akeso, Inc., Meituan and Tencent and net sales of SMIC, Yangtze Optical Fibre and Cable, Xiaomi Corp., Kingboard Laminates Holdings Ltd. and GenScript.
Source:Oct 14, 2026, 09:00 UTC
Hong Kong stocks recorded HK$38.71 billion in short selling, equal to 22% of HK$176.04 billion in turnover of shares available for short selling, compared with 23.1% the previous day.
Source:Oct 14, 2026, 05:30 UTC
Hong Kong stocks recorded HK$16.21 billion in short selling during the half-day session, equal to 22.1% of HK$73.18 billion in turnover of securities eligible for short selling, compared with 23.1% in the previous session.
Source:Oct 14, 2026, 01:24 UTC
Akeso, Inc. shares fell 6.67% to HK$98 at the market open.
Source:Oct 6, 2026, 08:12 UTC
Hong Kong stocks closed higher on October 6, 2026, with the Hang Seng Index up 240 points (1.0%) at 24,280, the Hang Seng Tech Index up 39 points (0.9%) at 4,223, and the China Enterprises Index up 77 points (1.0%) at 8,128 on turnover of HK$98.265 billion.
Sep 30, 2026, 10:25 UTC
Southbound Stock Connect investors recorded a net inflow of HK$1.407 billion into Tencent, HK$179 million into WuXi Biologics and HK$167 million into MINIMAX-W, while recording net outflows of HK$971 million from SMIC, HK$146 million from Zhipu and HK$17.16 million from Akeso.
Source:Sep 29, 2026, 04:12 UTC
Hong Kong stocks fell in the morning session, with the Hang Seng Index down 155 points (0.6%) to 24,486 and the Hang Seng Tech Index down 58 points (1.4%) to 4,237.
Source:Sep 29, 2026, 04:01 UTC
Akeso shares surged as much as 15.65% to HK$106.4 in morning trading after its overseas partner Summit Therapeutics received a US$2 billion strategic investment from AstraZeneca.
Source:Sep 29, 2026, 02:09 UTC
AstraZeneca and Summit Therapeutics announced they will jointly run a series of clinical trials combining ivonescimab with AstraZeneca's cancer therapies, and signed a preliminary agreement to explore ivonescimab combinations with several AstraZeneca antibody-drug conjugates.
Sep 28, 2026, 02:06 UTC
Akeso announced that the first patient has been enrolled in the global Phase III clinical trial of cadonilimab versus nivolumab for first-line treatment of gastric cancer.
Source:Sep 24, 2026, 04:12 UTC
Hong Kong stocks fell in the morning session on September 24, 2026, with the Hang Seng Index down 129 points to 24,704 and the Hang Seng Tech Index down 48 points to 4,330.
Sep 24, 2026, 00:18 UTC
At the 2026 WCLC in Seoul, Chinese innovative oncology drugs were presented, including Akeso's ivonescimab showing superior head-to-head results over pembrolizumab in first-line NSCLC, and Hansoh/Yilian B7-H3 ADC entering the plenary session.
Source:Sep 23, 2026, 23:59 UTC
Summit Therapeutics and Akeso revealed new study findings for ivonescimab that impressed Wall Street amid dueling data with a rival Merck medication.
Source:Sep 21, 2026, 05:00 UTC
Chinese biopharma stocks jumped in Hong Kong on Monday, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up more than 6%, HUTCHMED up 3%, Sino Biopharmaceutical up 8%, and the Hang Seng Biotech Index up more than 5%.
Source:Sep 21, 2026, 02:51 UTC
Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.
Source:Sep 21, 2026, 02:12 UTC
Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.
Source:Sep 17, 2026, 05:03 UTC
Akeso announced that its independently developed dual-antibody ADC drug AK158D1 (EGFR/Trop2) received approval from the Center for Drug Evaluation of the National Medical Products Administration to conduct a Phase I clinical study for the treatment of advanced malignant solid tumors.
Source:Sep 14, 2026, 03:57 UTC
Akeso Inc. shares opened 4.49% higher and rose as much as 4.82% to HK$96.55 on September 14, 2026, with 11.8951 million shares traded worth HK$1.109 billion.
Source:Sep 4, 2026, 05:33 UTC
CStone Pharmaceuticals reported first-half 2026 results with revenue of 1.806 billion yuan, up 27.9% year-on-year, and a net loss attributable to shareholders of 424 million yuan.
Source:Aug 27, 2026, 14:02 UTC
Akeso Inc. reported its first-half 2026 financial results, with revenue of RMB 1.806 billion, up 27.92% year-on-year, and a net loss of RMB 447 million, narrowing from a loss of RMB 588 million in the same period of 2025.
Jul 24, 2026, 08:40 UTC
Libo Medicine (09637) announced that its joint representatives have fully exercised the 15% over-allotment option, involving 8.5133 million H-shares at an issue price of HKD 22.6 per share, raising net additional proceeds of HKD 184.7 million to cover over-allotments in the international offering.
Source:Jul 20, 2026, 05:49 UTC
Akeso announced the dosing of the first patient in a Phase II clinical study of its TROP2/Nectin-4 bispecific ADC AK146D1 in combination with ivonescimab for advanced NSCLC.
Jun 15, 2026, 06:52 UTC
Akeso enrolled the first patient in a Phase Ib/II clinical study of its next-generation HER3 ADC AK138D1, alone or with ivonescimab, for advanced breast cancer.
Source:Jun 1, 2026, 07:02 UTC
Akeso is investing significantly to expand manufacturing of its lung cancer drug.
Source:May 31, 2026, 12:00 UTC
Akeso and Summit Therapeutics presented positive Phase 3 trial results for their experimental lung cancer drug ivonescimab at the American Society of Clinical Oncology annual meeting.